Table 1 Baseline characteristics of patients before starting medication with a SGLT2 inhibitor

Number of patients

27

Empagliflozin 18 (1 × 5 mg; 5 × 10 mg; 12 × 25 mg)

Dapagliflozin 9 (1 × 5 mg; 8 × 10 mg)

Age (years)

58 (52; 68)

Sex (male)

12 (43%)

BMI (kg/m²)

36.3 (32.6; 46.1)

Body weight (kg)

101.9 (87.8; 128.6)

Blood pressure

 Systolic (mmHg)

141 (129; 153)

 Diastolic (mmHg)

88 (76; 99)

Heart rate (1/min)

78 (70; 88)

Antidiabetic medication

 Insulin

20 (71.5%)

 Metformin

26 (92.9%)

 DPP4 inhibitor

12 (42.9%)

 GLP1 agonist

7 (25%)

Therapy with RAAS inhibitor

25 (93%)

 ACE inhibitor

20 (74%)

 Angiotensin II receptor antagonist

5 (18%)

Statin therapy

15 (56%)

HbA1c (%)

9.1 (8.1; 10.9)

Creatinine (mg/dL)

0.7 (0.6; 0.9)

Proteinuria (mg/g creatinine)

124 (78; 185)

Hematocrit (%)

42 (39; 44)

Uric acid (mg/dL)

4.7 (4.3; 5.9)

Cholesterol (mg/dL)

172 (160; 200)

 HDL cholesterol (mg/dL)

46 (37; 54)

 LDL cholesterol (mg/dL)

104 (92; 135)

Macrovascular complications: history of

 Coronary artery disease/myocardial infarction

10 (37%)

 Stroke

2 (7%)

 Peripheral artery disease

1 (4%)

Microvascular complications: history of

 Diabetic retinopathy

1 (4%)

 Diabetic nephropathy

8 (31%)

 Diabetic neuropathy

6 (23%)